The second High-Level Meeting on Antimicrobial Resistance (AMR) took place in New York on 26 September 2024 as the principal official, health-focused event during the UN General Assembly high-level week. The intergovernmental negotiations for the declaration were co-facilitated by Malta and Barbados. A political declaration for the meeting was produced highlighting the fact that AMR will cause even more global suffering, particularly in low- and middle-income countries. In this episode we will debrief and analyze the possible impact of these meetings and consequences for the future of AMR research and antimicrobial development.
Topics discussed:
- The political implications of the UN declaration on AMR.
- Comment of the scientific and public health impact of the declaration
- Elaborate on future antimicrobial research and development
Guests:
- John Rex, M.D. Chief Medical Officer, F2G Ltd; Operating Partner, Advent Life Sciences
- Prabha Fernandes, Ph.D. Board Member of GARDP (Global Antibiotic Research and Development Partnership).
Links:
- HLM on AMR at UNGA: The end of the beginning
- 29 April 2024: “R&D Implications: Global Burden of Disease is 28% Infectious!”
- 27 Sep 2024: “Without action, AMR costs go from $66b to $159b/yr by 2050”
This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal.
Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.
Subscribe to Editors in Conversation (free) on Apple Podcasts, Android, Spotify, Email.